Elekta clears deck for new CEO with order cancellation

11 Jun 2025, 20:13EKTAb.STSource

Swedish medical technology company Elekta has appointed Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

The appointment follows the departure of former CEO Gustaf Salford in March and a recent company decision to cancel 4.9 billion Swedish Kronor in orders.

Stock price
ELEKTA B
Loading chart...

Elekta said the cancellation was the result of a proactive review to improve the quality of its order backlog for better profitability and predictability.

The company stated these actions support its mid-term financial targets, including restoring gross margins to pre-pandemic levels.

Just-Bomholt previously served as CEO of dental technology company 3Shape and held senior executive positions at Falck A/S and A/P Moller Maersk, according to Elekta.

Elekta’s Founder and Chairman, Dr Laurent Leksell, said Just-Bomholt's "strategic leadership and international experience, combined with a proven ability to drive profitable growth and global expansion through customer-focused innovation and operational excellence, make him very well-suited to lead Elekta forward."

"I am honored to join Elekta, a company with a proud legacy and a powerful mission to improve the lives of people with cancer," Mr. Just-Bomholt said.

More from this issuer

Related coverage

Elekta's new chief executive is replacing three top executives, including the finance chief, in a broad management overhaul aimed at improving the Swedish medical-device maker's performance.

Elekta AB has introduced a new long-term incentive plan that ties executive bonuses to the sales of its advanced radiation-therapy technology, a move approved at its annual general meeting on Thursday.

Elekta AB reported a drop in first-quarter sales and profit margins, setting a challenging backdrop for incoming Chief Executive Jakob Just-Bomholt.

Elekta AB said it received U.S. regulatory clearance for its Leksell Gamma Knife radiosurgery system to treat a form of drug-resistant epilepsy in adults.